9月30日，荣晟环保盘中下跌2.02%，截至14:27，报13.58元/股，成交6375.19万元，换手率1.71%，总市 值37.02亿元。 资金流向方面，主力资金净流出180.46万元，特大单买入256.96万元，占比4.03%，卖出119.65万元，占 比1.88%；大单买入746.04万元，占比11.70%，卖出1063.81万元，占比16.69%。 荣晟环保今年以来股价涨15.49%，近5个交易日涨0.59%，近20日涨11.77%，近60日涨16.47%。 资料显示，浙江荣晟环保纸业股份有限公司位于浙江平湖经济开发区镇南东路588号，成立日期1998年 11月9日，上市日期2017年1月17日，公司主营业务涉及牛皮箱板纸、瓦楞原纸等再生包装纸产品以及瓦 楞纸板的生产制造,处于造纸产业链的中游。主营业务收入构成为：原纸及纸制品销售96.05%，蒸汽销 售3.58%，废料、污泥处理费及其他0.33%，蒸汽管道接口费0.04%。 荣晟环保所属申万行业为：轻工制造-造纸-大宗用纸。所属概念板块包括：太阳能、光伏玻璃、节能环 保、高派息、增持回购等。 截至6月30日，荣晟环保股东户数1.46万，较上期减少3 ...

Core Viewpoint - Ecovacs Robotics has shown significant stock performance with a year-to-date increase of 130.25%, reflecting strong market interest and financial growth [1][2]. Financial Performance - For the first half of 2025, Ecovacs achieved a revenue of 8.676 billion yuan, representing a year-on-year growth of 24.37% [2]. - The net profit attributable to shareholders for the same period was 979 million yuan, marking a substantial increase of 60.84% compared to the previous year [2]. Stock Market Activity - As of September 30, Ecovacs' stock price was 107.18 yuan per share, with a market capitalization of 61.774 billion yuan [1]. - The stock has experienced a trading volume of 3.79 billion yuan and a turnover rate of 0.63% on the same day [1]. - The stock has been active on the market, with a notable increase of 90.98% over the past 60 days [1]. Shareholder Information - As of June 30, the number of shareholders increased to 34,200, a rise of 5.54% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 5.25% to 16,633 shares [2]. Dividend Distribution - Since its A-share listing, Ecovacs has distributed a total of 2.021 billion yuan in dividends, with 944 million yuan distributed over the last three years [3]. Institutional Holdings - As of June 30, 2025, the sixth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 9.4739 million shares, an increase of 205,200 shares from the previous period [3]. - The seventh largest shareholder is Huaxia CSI Robotics ETF, with 5.1619 million shares, up by 922,100 shares [3]. - A new institutional investor, Fortune Balanced Preferred Mixed Fund, entered the top ten shareholders with 3.6056 million shares [3].

9月30日，天马科技盘中上涨2.06%，截至13:15，报16.34元/股，成交2.24亿元，换手率2.76%，总市值 82.09亿元。 天马科技所属申万行业为：农林牧渔-饲料-水产饲料。所属概念板块包括：增持回购、融资融券、养 鸡、水产养殖、预制菜等。 截至6月30日，天马科技股东户数1.71万，较上期增加2.41%；人均流通股29450股，较上期减少2.35%。 2025年1月-6月，天马科技实现营业收入29.74亿元，同比减少1.18%；归母净利润6021.70万元，同比增 长7.40%。 分红方面，天马科技A股上市后累计派现1.03亿元。近三年，累计派现3317.75万元。 天马科技今年以来股价涨28.26%，近5个交易日涨4.95%，近20日涨17.72%，近60日涨23.04%。 资料显示，福建天马科技集团股份有限公司位于福建省福清市上迳镇工业区，成立日期2005年12月13 日，上市日期2017年1月17日，公司主营业务涉及从事特种水产配合饲料研发、生产、销售。主营业务 收入构成为：畜禽饲料销售57.62%，特水饲料28.94%，养殖销售18.70%，食品销售7.20%，原料销售 1.86%，其 ...

中国外运所属申万行业为：交通运输-物流-跨境物流。所属概念板块包括：机器人概念、增持回购、一 带一路、无人驾驶、融资融券等。 截至6月30日，中国外运股东户数5.05万，较上期增加5.04%；人均流通股104337股，较上期减少 4.81%。2025年1月-6月，中国外运实现营业收入505.23亿元，同比减少10.37%；归母净利润19.47亿元， 同比增长0.10%。 分红方面，中国外运A股上市后累计派现97.19亿元。近三年，累计派现56.57亿元。 机构持仓方面，截止2025年6月30日，中国外运十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股4562.23万股，相比上期减少1351.21万股。易方达稳健收益债券A（110007）位居第七大 流通股东，持股2868.66万股，相比上期减少1072.28万股。南方中证500ETF（510500）位居第九大流通 股东，持股2350.24万股，为新进股东。 9月30日，中国外运盘中下跌2.14%，截至13:04，报6.39元/股，成交1.95亿元，换手率0.57%，总市值 464.69亿元。 资金流向方面，主力资金净流出929.45万元，特大单买 ...

Core Viewpoint - The stock price of Prise has shown significant fluctuations, with a year-to-date increase of 74.65% but a recent decline of 1.20% over the last five trading days [2]. Company Overview - Prise (Shanghai) Pharmaceutical Technology Development Co., Ltd. was established on February 22, 2013, and went public on May 17, 2022. The company is located at 500 Guangdong Road, 23rd Floor, World Trade Building, Huangpu District, Shanghai [2]. - The main business involves technology development, transfer, consulting, and services in the pharmaceutical field, with 100% of its revenue coming from services [2]. - The company belongs to the pharmaceutical and biotechnology sector, specifically in medical services and medical research outsourcing [2]. Financial Performance - For the first half of 2025, Prise reported a revenue of 390 million yuan, a year-on-year decrease of 1.08%, and a net profit attributable to shareholders of 54.16 million yuan, down 1.40% year-on-year [2]. - Since its A-share listing, Prise has distributed a total of 40.77 million yuan in dividends [3]. Shareholder Information - As of June 30, 2025, the number of shareholders for Prise was 8,571, a decrease of 1.88% from the previous period, with an average of 8,787 circulating shares per person, an increase of 1.91% [2]. - The top ten circulating shareholders include Tianhong Medical Health A, which holds 1.4287 million shares, a decrease of 17,600 shares from the previous period, and Rongtong Health Industry Flexible Allocation Mixed A/B, which holds 1 million shares, an increase of 100,000 shares [3].

Core Viewpoint - Transsion Holdings experienced a stock price decline of 2.01% on September 30, 2023, with a current price of 94.07 CNY per share and a total market capitalization of 107.27 billion CNY [1] Financial Performance - For the first half of 2025, Transsion Holdings reported a revenue of 29.077 billion CNY, representing a year-on-year decrease of 15.86% [2] - The net profit attributable to shareholders for the same period was 1.213 billion CNY, down 57.48% year-on-year [2] Stock and Shareholder Information - As of June 30, 2025, the number of shareholders for Transsion Holdings was 22,500, a decrease of 3.60% from the previous period [2] - The average number of circulating shares per shareholder increased by 3.74% to 50,756 shares [2] Dividend Distribution - Since its A-share listing, Transsion Holdings has distributed a total of 13.23 billion CNY in dividends, with 10.62 billion CNY distributed over the past three years [3] Major Shareholders - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder, holding 32.18 million shares, an increase of 2.26 million shares from the previous period [3] - Huaxia SSE STAR 50 ETF (588000) was the fifth largest shareholder, holding 25.20 million shares, a decrease of 0.58 million shares [3] - E Fund SSE STAR 50 ETF (588080) ranked seventh among major shareholders, with 18.89 million shares, an increase of 0.54 million shares [3]

Core Viewpoint - Spring Medical has shown significant stock performance with a year-to-date increase of 89.95%, indicating strong market interest and potential growth in the orthopedic medical device sector [1][2]. Company Overview - Spring Medical, established on February 12, 1998, and listed on December 30, 2021, is based in Tongzhou District, Beijing. The company specializes in the research, production, and sales of implantable orthopedic medical devices, primarily focusing on joint prosthetics and spinal implants [1]. - The main products include hip, knee, shoulder, and elbow joint prosthetics, as well as a full range of spinal internal fixation systems. The company exports its products to various regions, including Asia, South America, Africa, Oceania, and Europe [1]. Financial Performance - For the first half of 2025, Spring Medical reported a revenue of 488 million yuan, representing a year-on-year growth of 28.27%. The net profit attributable to shareholders was 114 million yuan, with a year-on-year increase of 44.85% [2]. - Since its A-share listing, the company has distributed a total of 359 million yuan in dividends, with 309 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased to 5,920, while the average circulating shares per person increased by 341.41% to 48,836 shares [2]. - Notable institutional shareholders include Ping An Low Carbon Economy Mixed A and Southern Medical Health Flexible Allocation Mixed A, with significant changes in holdings among the top ten circulating shareholders [3].

Core Viewpoint - China Jushi's stock price has shown significant growth this year, with a year-to-date increase of 55.96%, indicating strong market performance and investor interest [1][2]. Group 1: Stock Performance - As of September 30, China Jushi's stock price reached 17.39 CNY per share, with a trading volume of 3.47 billion CNY and a market capitalization of 696.15 billion CNY [1]. - The stock has experienced a 8.28% increase over the last five trading days, a 15.32% increase over the last 20 days, and a 38.68% increase over the last 60 days [1]. Group 2: Financial Performance - For the first half of 2025, China Jushi reported a revenue of 9.11 billion CNY, representing a year-on-year growth of 17.70%, and a net profit attributable to shareholders of 1.69 billion CNY, which is a 75.51% increase compared to the previous year [2]. - The company has distributed a total of 11.25 billion CNY in dividends since its A-share listing, with 4.83 billion CNY distributed over the last three years [2]. Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for China Jushi increased to 103,100, a rise of 6.61%, while the average number of circulating shares per person decreased by 6.20% to 38,836 shares [2]. - Major institutional shareholders include Hong Kong Central Clearing Limited, which holds 404 million shares, and several ETFs that have increased their holdings [2].

9月30日，华侨城A盘中上涨2.33%，截至10:03，报2.64元/股，成交8326.47万元，换手率0.47%，总市值 212.20亿元。 资金流向方面，主力资金净流入691.62万元，特大单买入466.78万元，占比5.61%，卖出573.84万元，占 比6.89%；大单买入2574.41万元，占比30.92%，卖出1775.73万元，占比21.33%。 华侨城A今年以来股价跌1.12%，近5个交易日涨3.53%，近20日涨16.81%，近60日涨14.78%。 华侨城A所属申万行业为：房地产-房地产开发-商业地产。所属概念板块包括：NFT概念、中盘、增持 回购、融资融券、特色小镇等。 责任编辑：小浪快报 截至9月19日，华侨城A股东户数10.64万，较上期增加0.71%；人均流通股64821股，较上期减少 0.71%。2025年1月-6月，华侨城A实现营业收入113.17亿元，同比减少50.82%；归母净利润-28.68亿 元，同比减少171.52%。 分红方面，华侨城AA股上市后累计派现165.03亿元。近三年，累计派现0.00元。 机构持仓方面，截止2025年6月30日，华侨城A十大流通股东中，中 ...

Core Points - TianKang Bio's stock price has increased by 15.48% year-to-date, but has seen a decline of 2.66% in the last five trading days [2] - The company reported a revenue of 8.847 billion yuan for the first half of 2025, representing a year-on-year growth of 10.68%, with a net profit of 338 million yuan, up 22.27% [2] - The company has distributed a total of 1.891 billion yuan in dividends since its A-share listing, with 598 million yuan distributed in the last three years [3] Company Overview - TianKang Bio, established on December 28, 2000, and listed on December 26, 2006, is located in Urumqi, Xinjiang, and specializes in the production and sales of biological vaccines for livestock, feed, and plant protein [2] - The revenue composition of TianKang Bio includes 32.20% from the pig breeding industry chain, 27.51% from feed, 16.37% from protein and oil processing, 14.75% from corn, 5.44% from veterinary drugs, and 3.40% from other sources [2] - As of September 19, 2025, the number of shareholders is 62,700, a decrease of 9.64% from the previous period, with an average of 21,770 circulating shares per person, an increase of 10.67% [2] Institutional Holdings - As of June 30, 2025, the sixth largest circulating shareholder is Guotai Zhongzheng Livestock Breeding ETF, holding 15.5491 million shares, an increase of 641,000 shares from the previous period [3] - The ninth largest circulating shareholder is Harvest Agricultural Industry Stock A, holding 10.2945 million shares, an increase of 630,100 shares [3] - The tenth largest circulating shareholder is Southern Zhongzheng 1000 ETF, holding 10.0839 million shares, an increase of 1.8978 million shares [3]